The Brand Name MOXICIP Has Generic Salt :: Moxifloxacin
MOXICIP Is From Company Cipla Priced :: Rs. 347.75
MOXICIP have Moxifloxacin is comes under Sub class Quinolones of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Quinolones
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Intra-abdominal infections, Chronic bronchitis, Acute bacterial sinusitis, Community-acquired pneumonia, Skin and skin structure infections, Typhoid Fever
Drug Dose ::
• The dose of Moxifloxacin is 400 mg once every 24 hours. The duration of therapy depends on the type of infection as described bellow-• In Acute Bacterial Sinusitis Moxifloxacin 400 mg is given once daily for 10 days.• In Acute Bacterial Exacerbation of Chronic Bronchitis Moxifloxacin 400 mg is given once daily for 5 days. • In Community Acquired Pneumonia Moxifloxacin 400 mg is given once daily for 7-14 days. • In Uncomplicated Skin & Skin Structure infections Moxifloxacin 400 mg is given once daily for 7 days.• In Complicated Skin & Skin Structure infections Moxifloxacin 400 mg is given once daily for 7-21 days.• In Complicated Intra-Abdominal infections Moxifloxacin 400 mg is given once daily for 5-14 days. • In Typhoid Fever Moxifloxacin 400 mg is given once daily for 10-14 days.
Hypersensitivity; child, adolescent; pregnancy, lactation.
Drug Precautions ::
Maintain adequate fluid intake; exposure to strong sunlight/sunlamp. Epilepsy, history of CNS disorders, DM. Not recommended in severe hepatic impairment. May worsen myasthenia gravis. Discontinue in case of tendon pain, inflammation or rupture. High level of resistance with S. aureus infections. Increased risk of tendon inflammation/rupture especially in elderly taking corticosteroids. Caution in patients with proarrhythmic conditions e.g. clinically significant bradycardia or acute MI. Existing QT prolongation, bradycardia, heart failure with reduced left ventricular ejection fraction; uncorrected hypokalaemia. Avoid concomitant usage with drugs that are known to prolong QT interval. Prolonged use may increase risk of fungal or bacterial superinfection.
Drug Side Effects ::
GI disturbances, CNS effects, hypersensitivity-type reactions, reversible arthralgia, abnormal liver function tests, hepatitis, haematological disturbances, tachycardia, superinfection, pain and irritation at the Inj site, tendon damage, phloebitis and thrombophloebitis, peripheral neuropathy, photosensitivity, abdominal pain, headache, vaginitis.
Pregnancy category ::
Drug Mode of Action ::
Moxifloxacin inhibits the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair and recombination.
Drug Interactions ::
Additive effect on QT interval prolongation w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Decreased absorption and bioavailability w/ Al- or Mg-containing antacids, or Fe or Zn preparations. Concomitant use of corticosteroids increases the risk of severe tendon disorders esp in elderly (>60 yr). Decreased absorption w/ sucralfate or didanosine. Potentially Fatal: Concurrent use of class Ia (e.g. quinidine, procainamide) or III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents) may cause additive effect on QT interval prolongation.